That is one of the key questions from the IVI”s recent Value Blueprint paper titled “Prioritized Attributes to Better Define and Measure Innovation in Health Technology Assessment“. The expert roundtable convened by IVI examines not only whether there is a consensus about how to implement the value element (“method readiness”) but also if their is robust data to estimate this value element in practice (“data quality”). These were the conclusions of the IVI expert panel:
Access, affordability, optimal treatment pathway, clinical and economic burden were all considered attributes with good data. However, there was inconsistency across stakeholders and diseases regarding the use quality data and validated methodologies.
Some emerging data sources and methods were found to be useful in improving the health and well-being patients. Family spillover5 and reduced patient burden were some attributes that had emerging data sources, but not methods.
Family spillover is when a disease or its management has an impact on not only the patient, but also the family members who may or not be providing care. The impact on wider…